Business

Merck completes USD 2.7b acquisition of Terns Pharmaceuticals for BCR-ABL1 inhibitor TERN-701

Merck (NYSE: MRK) has completed the acquisition of Terns Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, through an all-cash tender offer at USD 53.00 per share, with the transaction expected to generate an asset acquisition charge of approximately USD 5.8 billion to Merck's research and development expense in the second quarter of 2026. The deal adds TERN-701, an oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase I/II development for chronic myeloid leukemia (CML), to Merck's hematology pipeline alongside three existing Phase III candidates. The deal was first announced in March this year.

Merck completed the acquisition of Terns through a two-step structure: a cash tender offer executed through a wholly-owned subsidiary, followed by a back-end merger in which Terns became a wholly-owned subsidiary of Merck. As of the tender offer expiration at one minute after 11:59 p.m. Eastern Time on May 4, 2026, 100,091,794 shares of Terns common stock had been validly tendered, representing approximately 86.36% of total issued and outstanding shares. All remaining shares were converted into the right to receive USD 53.00 per share upon merger completion. Terns common stock has been delisted from the Nasdaq Global Select Market.

The transaction is accounted for as an asset acquisition rather than a business combination, resulting in a charge to research and development expense of approximately USD 5.8 billion, or approximately USD 2.35 per share, reflected in both second quarter and full year 2026 GAAP and non-GAAP results. Merck also disclosed an additional negative EPS impact of approximately USD 0.12 per share in 2026, representing costs associated with advancing TERN-701 and financing.

Geographic rights acquired by Merck cover all territories outside Greater China. Terns had previously licensed TERN-701 development and commercialization rights for mainland China, Taiwan, Hong Kong, and Macau to Hansoh Pharma. Prior to the Merck acquisition, Terns amended its original license agreement with Hansoh to convert a non-exclusive, royalty-free license to certain Hansoh patents into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for all territories outside the Hansoh territory. Merck does not hold Greater China rights to TERN-701.

TERN-701: mechanism and clinical status

TERN-701 is an oral allosteric BCR::ABL1 inhibitor designed to bind to the ABL myristoyl pocket, a site distinct from the ATP-binding site targeted by most approved tyrosine kinase inhibitors in CML. Allosteric binding at the myristoyl pocket locks the ABL kinase in an inactive conformation, a mechanism that may offer activity in patients who have developed resistance to ATP-competitive TKIs, provided the resistance does not involve the T315I gatekeeper mutation.

The US FDA granted TERN-701 Breakthrough Therapy Designation for the treatment of adults with Philadelphia chromosome-positive CML in the chronic phase without the T315I mutation who have been previously treated with two or more tyrosine kinase inhibitors. This designation is based on data from the ongoing Phase I/II CARDINAL trial, which continues to enroll patients across the relevant population.

The AllSci BriefSystematic R&D and deal news. Daily.

CML is driven by constitutive activation of the BCR::ABL1 fusion protein, arising from the Philadelphia chromosome translocation between chromosomes 9 and 22. Approved ATP-competitive TKIs — including imatinib, dasatinib, nilotinib, bosutinib, and ponatinib — have substantially altered the disease course, but resistance and intolerance remain clinical challenges in the multiply pretreated setting. Asciminib (Scemblix), approved by the FDA in 2021, established allosteric myristoyl pocket inhibition as a validated mechanism in this setting, including a formulation active against T315I. TERN-701's differentiation claim relative to asciminib, particularly in the T315I-negative, multiply pretreated population, will depend on data from CARDINAL.

The BCR::ABL1 inhibitor field has attracted structured deal activity from major pharmaceutical companies in recent years, reflecting the clinical and commercial value of the multiply pretreated CML segment. In June 2024, Takeda Pharmaceutical entered an option-to-acquire exclusive global license agreement with Ascentage Pharma for olverembatinib, a third-generation oral BCR-ABL TKI targeting the same disease setting, with an upfront option payment of USD 100 million and potential total value of approximately USD 1.3 billion including the option exercise fee and milestones.

Strategic fit for Merck

The Terns acquisition extends Merck's cancer drug development activity in hematology beyond its current Phase III candidates. Merck is advancing bomedemstat (MK-3543), an oral lysine-specific demethylase 1 inhibitor; nemtabrutinib (MK-1026), a non-covalent Bruton's tyrosine kinase inhibitor; and zilovertamab vedotin (MK-2140), an antibody-drug conjugate targeting ROR1, all in Phase III trials across leukemias, lymphomas, and myeloproliferative neoplasms. MK-1045, a CD19xCD3 T-cell engager, is in Phase Ib/II evaluation. TERN-701 adds a mechanistically distinct oral allosteric BCR::ABL1 program to this portfolio, targeting a patient population — multiply pretreated, T315I-negative, chronic-phase CML — not directly addressed by Merck's existing hematology pipeline assets.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article